SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC
Position in BBIO — BridgeBio Pharma, Inc.
CIK 1638555
Boston, MA
Position in BBIO
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$26,201,230
-$36,045,873 QoQ
Shares Held
352,831
-56.6% QoQ
Ownership
0.180%
of shares outstanding
% of Portfolio
1.23%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2025
5 quarters on record
Voting authority
Sole 84%
Shared 0%
None 16%
Common Shares in BBIO Over Time
Shares Held
Position Value (USD)
Derivatives in BBIO
reported options exposure · as of Mar 31, 2026CallValue
$0
CallShares
0
PutValue
$11,139,000
PutShares
150,000
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC holds $272,348,421 across 4 Biotechnology names. BBIO ranks #4 (9.6% of the industry book) .
All Filings in BBIO
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $11,139,000 | 150,000 | Put | Sole | 2026-05-15 | |
| 2026-03-31 | $26,201,230 | 352,831 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $62,247,103 | 813,794 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $41,900,517 | 806,710 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $32,719,429 | 757,745 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $39,049,995 | 1,129,592 | Shares | Sole | 2025-05-15 | |
| No filing history on record for this holder in this stock. | ||||||